VAS203 + Saline
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Traumatic Brain Injury
Conditions
Traumatic Brain Injury
Trial Timeline
Jun 1, 2016 → Jun 30, 2020
NCT ID
NCT02794168About VAS203 + Saline
VAS203 + Saline is a phase 3 stage product being developed by ICON plc. for Traumatic Brain Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT02794168. Target conditions include Traumatic Brain Injury.
What happened to similar drugs?
8 of 16 similar drugs in Traumatic Brain Injury were approved
Approved (8) Terminated (5) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02794168 | Phase 3 | Completed |
Competing Products
20 competing products in Traumatic Brain Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 27 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 32 |
| Celecoxib | Astellas Pharma | Pre-clinical | 26 |
| Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product | Sun Pharmaceutical | Phase 1 | 29 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 36 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 43 |
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 27 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 35 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 27 |
| Placebo + sertraline | Johnson & Johnson | Approved | 35 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 40 |
| Adjunctive asenapine | Merck | Approved | 43 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 18 |
| Alendronate | Merck | Approved | 39 |
| Iloperidone + Placebo | Novartis | Phase 2 | 27 |
| AMG 334 | Novartis | Phase 2 | 35 |
| Rivastigmine | Novartis | Phase 3 | 40 |
| Rivastigmine | Novartis | Approved | 43 |
| Balovaptan + Placebo | Roche | Phase 2 | 35 |
| Erenumab | Amgen | Phase 2 | 35 |